Jovita Ezirim-Salamialofoje, NP
Psychiatric/Mental Health · Los Angeles, CANPI 1114320124
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,669 of the $161,519 with a category attached, or 76.6%. 14 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 50.6% of the total. Reporting peaked in 2023 at $43,489 and has fallen 53.9% since, to $20,065 in 2025. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 698 payments — averaging $231.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$82K
- Teva Pharmaceuticals USA, Inc.$70K
- Johnson & Johnson$4K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $2K from 8 others
What the payments were for
- Consulting fees$14,4589%
- Speaking & faculty fees$123,66977%
- Travel & lodging$5,8424%
- Food & beverage$17,27211%
- Education$2780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 113 | $81,742 |
| Teva Pharmaceuticals USA, Inc. | 255 | $69,947 |
| Johnson & Johnson(2 entities) | 121 | $3,508 |
| Alkermes, Inc. | 46 | $1,769 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 43 | $1,377 |
| Otsuka America Pharmaceutical, Inc. | 53 | $1,306 |
| E.r. Squibb & Sons, L.L.C. | 16 | $737 |
| Lundbeck LLC | 24 | $570 |
| AbbVie | 8 | $142 |
| Sunovion Pharmaceuticals Inc. | 7 | $119 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $103 |
| Luye Pharma (USA) Ltd. | 5 | $92 |
| Indivior Inc. | 4 | $78 |
| Harmony Biosciences LLC | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$80,043
- UZEDY$30,618
- Austedo XR$25,042
- AUSTEDO$10,012
- LYBALVI$2,377
- ARISTADA$953
- INVEGA SUSTENNA$535
- CAPLYTA$378
- COBENFY$347
- INVEGA TRINZA$278
- ARISTADA INITIO$238
- ABILIFY MAINTENA$238
- ABILIFY ASIMTUFII$238
How this compares
$161,519 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 37 | $295,997 |
| Abilify MaintenaAripiprazole | 42 | $106,201 |
| Austedo XrDeutetrabenazine | 16 | $85,002 |
| Invega SustennaPaliperidone Palmitate | 19 | $59,708 |
| Clozapine OdtClozapine | 123 | $41,561 |
| Lurasidone Hcl | 67 | $16,352 |
| Clozapine | 49 | $8,336 |
| Divalproex Sodium ErDivalproex Sodium | 61 | $2,011 |
| Quetiapine Fumarate | 150 | $1,710 |
| Aripiprazole | 42 | $1,615 |
| Clonazepam | 94 | $1,504 |
| Divalproex Sodium | 24 | $993 |
| Benztropine Mesylate | 61 | $898 |
| Propranolol Hcl | 30 | $750 |
| Trazodone Hcl | 112 | $704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $81,742 | $295,99737 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,306 | $106,20142 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $69,947 | $85,00216 claims |
| Johnson & JohnsonInvega Sustenna | $3,508 | $59,70819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Los Angeles
- Sarah KoLos Angeles$34K
- Prince OkosunLos Angeles$12K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Jonathan LlamasPasadena$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.